Currently serving as Chairman of the board, James is a member of the team at Nottingham Technology Ventures Ltd, the subsidiary company of the University of Nottingham responsible for the formation of, and investment in spin out companies.
A life scientist by training he has 18 years of experience working both in industry and university technology transfer, including holding a number of board positions.
Stephen Jackson is a Founder and Director of Neurotherapeutics Ltd, Professor of Cognitive Neuroscience at the University of Nottingham, and has more than 30 years research experience investigating human sensorimotor function in health and disorder.
He is the first recipient of the ‘Dirk Bakker Visiting Professorship’ awarded by the Stichting Neuropsychologie Nederland (Dutch Neuropsychology Society) and is currently a member of the Scientific Advisory Board of the Federation of European Societies for Neuropsychology (FESN). Stephen has previously served as President of the British Association for Cognitive Neuroscience (BACN), Director of the University of Nottingham’s Institute of Neuroscience, and from 2007–2012 he chaired a European Research Network Programme (RNP) on ‘Human Sensorimotor Function in Health and Disease’.
His research has been funded by many funding organisations including: the Wellcome Trust; NIHR; MRC; BBSRC; BUPA Foundation; Tourettes Association of America; and Tourettes Action, and he has provided scientific advice and guidance to a wide range of governmental, industrial, academic, and charitable organisations, including the UK Ministry of Defence, Unilever, the MRC and Wellcome Trust. From 2009 – 2012 Stephen was appointed ‘Distinguished Overseas Professor’ at Korea University, South Korea. His role was to assist in establishing a new centre for research and teaching excellence in ‘Brain and Cognitive Engineering’ at Korea University and to lead a research team investigating Brain Plasticity Mechanisms.
Professor Georgina Jackson is a Founder and Director of Neurotherapeutics Ltd and Professor of Cognitive Neuropsychology within the School of Medicine, University of Nottingham.
She has an extensive track-record of externally funded research investigating the brain mechanisms underlying goal-directed behaviour in health and disorder. Her work focuses on understanding the development of cognitive control processes (often referred to as executive function) during childhood and adolescence and how these processes are affected by neurodevelopmental conditions such as Tourette syndrome.
She has been funded by: the Wellcome Trust; MRC, BBSRC, ESRC, amongst others and has been actively involved in Tourette syndrome research for over fifteen years. In 2009 she was commissioned by UK charity Tourettes Action, with funding from the Big-Lottery Fund, to examine the psycho-social experiences of young people with Tourette syndrome and she co-authored a Healthcare Technology Association report on the clinical effectiveness and patients perspectives on treatments for TS. Georgina has previously served as General Secretary of the British Neuropsychological Society and is currently a member of the Board of Trustees of Tourettes Action.
Ian Rhodes is a Non Executive Director for Neurotherapeutics Ltd, he brings over 35 years’ experience of working in high technology industries.
As an ex CEO of McLaren Applied Technologies and former Senior Partner at PA Consulting Group bringing valuable input at board level.
Paul has 30 years of global experience in the Medical device and pharma field working previously for Baxter Healthcare and lately through his own consultancy working with start-ups and established businesses.
Focuses on medical solutions that make a dramatic change for the individuals receiving them. Passionate about the life cycle management of medical devices with a background in engineering.
Dr. David Moser is an experienced engineer in the areas of Robotics and Medical devices. He brings over 17 years of experience developing wearable assistive technologies and medical devices.
He is former Director of Research and Technology at Blatchford where he led the development of some of the world’s most advanced prosthetics and a succession of award-winning products including the RAEng MacRobert Award finalist in 2010, winner in 2016 and the US Medical Device excellence award in 2017.
He is a Chartered Engineer and a Visiting Professor at the University of Southampton. He holds over 25 patents and has published extensively in the areas, of prosthetics, body interface technologies, Robotics, physical rehabilitation, and digital health. He is responsible for technology and new product development.
Dr. Barbara Morera carried out the research studies leading to the development of the approach that Neurotherapeutics Ltd will develop into a wearable medical device to control symptoms in Tourette syndrome.
She is responsible for the management of product development and clinical studies that aim to improve the quality of life of people with Tourette syndrome.
Claire has over 19 years of experience in quality management practices, ISO certification and regulatory affairs predominantly within the medical device and pharmaceutical industries.
She is responsible for our Quality Management System and ISO 13485 certification.
Ciara was involved in the Neurotherapeutics Ltd clinical trial in 2022 as a psychology assistant, following her Masters in Developmental Psychology at the University of Nottingham.
Ciara worked alongside participants with Tourette’s Syndrome to gain valuable feedback about their experience using a wearable device and she was involved in collecting and analysing data from the trial.
Ciara is conducting research on behalf of the company to aid the further development of a wearable medical device.